Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02374021 · ClinicalTrials.gov registry record · Phase 4
Treatments Against RA and Effect on FDG-PET/CT
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 159
- Enrollment target
NCT02374021 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 159 participants.
The verdict
NCT02374021, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 159 participants
- Enrollment target
Study Summary
In a randomized controlled clinical trial, investigators will compare the effects on \[18F\]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening).
Interventions
- DRUG Adalimumab
- DRUG Methotrexate
- DRUG Hydroxychloroquine
- DRUG Sulfasalazine
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02374021
The ClinicalTrials.gov registry entry for NCT02374021 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Adalimumab is the first listed.
NCT02374021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02374021 about?
NCT02374021 is a clinical study titled "Treatments Against RA and Effect on FDG-PET/CT". In a randomized controlled clinical trial, investigators will compare the effects on \[18F\]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two com...
What is the current status of trial NCT02374021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 159 participants. The study started on 2016-07. Estimated completion is 2021-05.
What interventions are being tested in trial NCT02374021?
The interventions under investigation include: Adalimumab (DRUG), Methotrexate (DRUG), Hydroxychloroquine (DRUG), Sulfasalazine (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT02374021?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.